CN103834638A - Single nucleotide polymorphic site rs7574865 related to liver cancer susceptibility and application thereof - Google Patents
Single nucleotide polymorphic site rs7574865 related to liver cancer susceptibility and application thereof Download PDFInfo
- Publication number
- CN103834638A CN103834638A CN201210493218.6A CN201210493218A CN103834638A CN 103834638 A CN103834638 A CN 103834638A CN 201210493218 A CN201210493218 A CN 201210493218A CN 103834638 A CN103834638 A CN 103834638A
- Authority
- CN
- China
- Prior art keywords
- primer
- seq
- sequence
- nucleic acid
- liver cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the gene field of biological technologies, and relates to a single nucleotide polymorphic site (SNP) related to liver cancer susceptibility and application thereof. The invention firstly provides a partial sequence (shown as SEQ. ID. NO.1) of an STAT4 gene and an SNP site rs7574865 of the gene (the sequence is shown as SEQ. ID. NO.2). The invention also provides a method for detecting the SNP site, specificity nucleic acid primers and a UEP (ultra high molecular weight polyethylene) primer, wherein the sequences of the specificity nucleic acid primers are shown as SEQ.ID.NO.3 and SEQ.ID.NO.4, the sequence of the UEP primer is shown as SEQ.ID.NO.5. The invention also relates to a detection kit for the SNP site rs7574865 and application thereof. The method for genotyping of the rs7574865 site is simple and convenient and rapid, and is accurate and clear in result, and the single nucleotide polymorphic site rs7574865 provides a new way for identifying the liver cancer susceptibility and preventing and treating the liver cancer.
Description
Technical field
The invention belongs to the gene field of biotechnology, be specifically related to a single nucleotide polymorphism relevant to liver cancer susceptibility (single nucleotide polymorphism, SNP) site and application thereof.
Background technology
Liver cancer is the seventh-largest common cancer in the world, in the relevant cause of the death of cancer, is positioned at the 3rd (Yang JD, Roberts LR.Hepatocel lular carcinoma:A global view.Nat Rev Gastroenterol Hepatol.2010; 7:448-58.); the annual expectation in whole world new cases 74.83 ten thousand people; the number of cases of dying of illness approximately 69.59 ten thousand people; wherein liver cancer case more than half all concentrates on China (Jemal A; Bray F, Center MM, Ferlay J; Ward E, Forman D.Global cancer statistics.CA Cancer J Clin.2011; 61:69-90.).
Worldwide, chronic viral hepatitis B and chronic hepatitis C are the principal risk factors of liver cancer, and almost 80% hepatocarcinoma patient all has hepatitis B or the third hepatitis history, and its reason of suffering from cancer of 54% hepatocarcinoma patient is the infection of hepatitis B virus; But in China; exceed 80% hepatocarcinoma patient and all have hepatitis B medical history (Tanaka M; Katayama F; Kato H; Tanaka H; Wang J, Qiao YL, Inoue M.Hepatitis B and C virus infection and hepatocellular carcinoma in China:a review of epidemiology and control measures.J Epidemiol.2011; 21:401-16.).
China is hepatitis B big country in the world, the positive rate of hepatitis B surface antigen in general population (HBsAg) is up to 9%, there are 1.2 hundred million people once to infect hepatitis B virus, wherein have 3,000 ten thousand people to change into for chronic viral hepatitis B, account for all hepatitis B patients' in the whole world 1/3rd.Suffer from chronic viral hepatitis B after 5 years, have the people of 10-20% will develop into liver cirrhosis; Chronic viral hepatitis B and the patient with liver cirrhosis of 6-15% of having an appointment can develop into liver cancer (Liu J, Fan D.Hepatitis B in China.Lancet.2007; 369 (9573): 1582-3.).
The risk factors that hepatitis B develops into liver cancer have a lot, and wherein inherited genetic factors is the important risk factor that hepatitis B develops into liver cancer.Research shows, than the hepatitis B patient who there is no liver cancer family history, there is the B-type hepatitis people of liver cancer family history to develop into relative risk (the relative risk of liver cancer, RR) be 2.41, have more than two relatives be the B-type hepatitis people of liver cancer patient develop into liver cancer RR up to 5.55(Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ.Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives.J Natl Cancer Inst.2000, 92:1159-64.).
Causing one of physical basis of heredity of interindividual variation is exactly SNP.SNP refers to that in genomic level, by the caused DNA sequence polymorphism of variation of single core thuja acid, it is modal one in the heritable genome mutation of the mankind, accounts for the more than 90% of all known polymorphisms.SNP extensively exists in human genome; in average every 500～1000 base pairs, just there is 1; estimate that its sum can reach 3,000,000 even more (Collins FS; Brooks LD, Chakravarti A.A DNApolymorphism discovery resource for research on human genetic variation.Genome Res.1998; 8 (12): 1229-31.).At present, SNP is the important evidence of research mankind common disease heritable variation.But the report being associated with liver cancer so far there are no the STAT4 gene the present invention relates to, also about the dependency of pleomorphism site and liver cancer on STAT4 gene and for the report of detection method and the detection kit of concrete SNP.
Summary of the invention
The object of the present invention is to provide a kind of STAT4 gene order relevant to liver cancer susceptibility, by the sequence research of SNP site rs7574865, propose a kind of method of the examination that is beneficial to liver cancer high risk population, for the susceptibility of liver cancer is identified, and prevent and treat the new approach that provides.
Research of the present invention shows, STAT4 gene is relevant to the susceptibility of liver cancer.
First the present invention provides the portion gene sequence on the STAT4 gene relevant to liver cancer susceptibility, and the nucleotide sequence of this gene order is as shown in SEQ.ID.NO.1, and its 501st is T or G.
The present invention also provides a SNP site rs7574865 on the STAT4 gene relevant to liver cancer susceptibility.Rs7574865 is positioned on the 3rd intron of STAT4 gene; Rs7574865 base is T or G; The nucleotide sequence of rs7574865 is referring to http://genome.uscs.edu/ database, and its sequence is as shown in SEQ.ID.NO.2.
The present invention also provides the specific nucleic acid primer that detects a SNP site: SEQ.ID.NO.3, SEQ.ID.NO.4, and UEP primer (single-basic extension primer) SEQ.ID.NO.5, to amplify specifically the amplified production in this SNP site.
The present invention also provides a kind of SNP of detection method of site rs7574865, and the step that obtains rs7574865 sequence is followed successively by:
(1) utilize the DNA of specific nucleic acid primer (SEQ.ID.NO.3, SEQ.ID.NO.4) amplified sample;
(2) get the product of step (1), utilize UEP primer (be single-basic extension primer, sequence is shown in SEQ.ID.NO.5) to carry out single-basic extension;
(3) product of mass spectrometric detection step (2).
Wherein, the amplification condition of step (1) can be: 95 ℃ of 2min; 95 ℃ of 0.5min, 56 ℃ of 0.5min, 72 ℃ of 1min, 45 circulations; 72 ℃ of 5min, 25 ℃ of ∞ (infinitely) min(minute).
Wherein, the product of step (1) carries out single-basic extension conventionally after purifying again.
Wherein, the condition of the single-basic extension described in step (2) can be: 94 ℃ of 30s; 94 ℃ of 5s, 52 ℃ of 5s-80 ℃ of 5s, internal recycling 5 times, outer loop 40 times; 72 ℃ of 180s; 25 ℃ of ∞ (infinitely) s(second).
Wherein, the concrete steps of acquisition rs7574865 sequence can be as follows:
In STAT4 gene, select SNP site rs7574865;
According to corresponding base sequence synthetic primer SEQ.ID.NO.3, SEQ.ID.NO.4 and UEP primer SEQ.ID.NO.5; PCR reaction system 5ul:0.625ul10 × TaqBuffer, 0.125mM dNTP, 0.12ul10nM PCR primer Mix, 0.32525nM MgCl
2, 0.1ul5U/ML Hotstar enzyme, uses ddH
2o supplies 5ul; PCR reaction conditions: 95 ℃ of 2min; 95 ℃ of 0.5min, 56 ℃ of 0.5min, 72 ℃ of 1min, 45 circulations; 72 ℃ of 5min, 25 ℃ of ∞ min; SAP purification reaction system 2ul:0.17ul10 × SAPBuffer, 0.31U/ul SAP enzyme (shrimp alkali enzyme), uses ddH
2o supplies 2ul; SAP purification reaction condition: 37 ℃ of 40min, 85 ℃ of 5min, 25 ℃ of ∞ min;
Single base extension system 2ul:0.210 × iPlexBuffer, 0.2iPlex Termination, 0.33100uM stops primer Mix, and 0.041iPlex Enzyme, uses ddH
2o supplies 2ul; Single base extension condition: 94 ℃ of 30s; 94 ℃ of 5s, 52 ℃ of 5s-80 ℃ of 5s, internal recycling 5 times, outer loop 40 times; 72 ℃ of 180s; 25 ℃ of ∞ s;
By reaction product 15nL altogether, after resin purification, SpectroCHIP chip loading; Pass through
mALDI-TOFMass Spectrometry carries out mass spectrometric detection, and obtains the somatotype data of SNP site rs7574865.
The present invention also provides a kind of SNP of detection test kit of site rs7574865, and described test kit comprises the specific nucleic acid primer of sequence as shown in SEQ.ID.NO.3, SEQ.ID.NO.4.
Described test kit also comprises UEP primer, and its sequence is as shown in SEQ.ID.NO.5.
Described test kit can also comprise the damping fluid of PCR.
Described test kit can also comprise standard reagent and specification sheets, etc.
The invention provides the application of mentioned reagent box, utilize this test kit to determine the sequence of SNP site rs7574865: the DNA of amplified sample; Then carry out single-basic extension; Last mass spectrometric detection somatotype.
Wherein, can utilize the DNA of above-mentioned specific nucleic acid primer amplification sample, utilize UEP primer to carry out single-basic extension.
Experiment shows, the present invention can be special, efficient detection goes out rs7574865 pleomorphism site.Utilize Taqman method and direct Sequencing, detect same sample, gene type comes to the same thing.
The invention provides the application of SNP site rs7574865, carry out the gene type of SNP site rs7574865 by extracting experimenter's genomic dna.Wherein, the individuality that rs7574865 base is G is liver cancer Susceptible population, and the individuality that rs7574865 base is T is the non-Susceptible population of liver cancer.
Advantage of the present invention:
1) according to primer sequence provided by the invention can be special, efficient detection goes out rs7574865 pleomorphism site.
2) the gene type result that detects SNP site rs7574865 according to the present invention is judged the method for liver cancer Susceptible population, can carry out examination to the hepatitis B patient who does not show clinical tumor symptom, be applied to diagnosis for liver cancer and whether hepatitis B patient is had to liver cancer susceptibility and pass judgment on, thereby be conducive to prevention, the early diagnosis and therapy of disease.
3) be positioned near the DNA sequence dna of rs7574865 pleomorphism site and also have many SNP site, these information play a role the generation development to judging liver cancer.
Embodiment
Below in conjunction with specific embodiment, to further illustrate the present invention.Should be understood that following examples are only not used in and limit the scope of the invention for the present invention is described.
The gene type of embodiment 1.SNP site rs7574865
The gene type that carries out SNP site rs7574865 by extracting experimenter's genomic dna, result shows: the Susceptible population that the individuality that rs7574865 base is G is liver cancer.
Specific practice is:
1. the extraction of genomic dna
Experimenter extracts 2-3ml by peripheric venous blood, adopts QIAamp Blood Mini Kit250(QIAGEN, Germany) test kit extraction genomic dna ,-20 ℃ of preservations.
2.SNP gene type
Select PCR reaction and single base expansion primer according to the sequence information of SNP, and synthetic in biotechnology (Shanghai) Co., Ltd..Primer after synthetic carries out PCR with sample DNA and reacts, and mixed reaction product is carried out SNP gene type on Sequenom iPLEX instrument (Sequenom company).Specific experiment flow process is as follows:
(1) design of primers: be multiple reaction Automated Design PCR primer (SEQ.ID.NO.3; SEQ.ID.NO.4) and
gold single-basic extension primer (SEQ.ID.NO.5);
(2) PCR reaction:
(A) PCR reaction solution (Mix): add successively from top to bottom unit according to the order in following table: ul
(B) 5ul PCR reaction system: get 3ulPCR reaction solution Mix and join in each hole of 384 orifice plates, 96 orifice plate DNA samples are transferred in 384 orifice plates with the 8 road volley of rifle fires according to the order of 96 orifice plate to 384 orifice plate application of sample tables, every hole 2ul, be made into the reaction system of 5ul, 2000 leave and put into ABI9700PCR instrument after heart 1min and carry out pcr amplification.
(C) loop parameter
(3) SAP purification reaction
(A) reaction system, with preparing SAP enzyme (shrimp alkali enzyme) Mix:(unit: ul according to following order in 1.5ml EP pipe)
(B) Mix is evenly distributed in to 8 hole platoon pipes, opens gently 384 orifice plate sealed membranes, the Mix that gets 2ul with the 8 road volley of rifle fires joins in each hole.Getting new sealed membrane scraper plate is tamping side and four angles.2000 leave after heart 1min, carry out SAP enzymic digestion in PCR instrument.
(C) loop parameter
| Temperature (° C) | Time (min) | Cycle |
| 37 | 40 | 1 |
| 85 | 5 | 1 |
| 25 | ∞ | 1 |
(4) single base extension
(A) reaction system is prepared single base extension Mix:(unit: ul according to following order in 1.5mlEP pipe)
(B) Mix is evenly distributed in 8 hole platoon pipes, opens gently sealed membrane, the Mix that gets 2ul with the 8 road volley of rifle fires joins in each hole.Get new sealed membrane the side of 384 orifice plates and four angles are tamping, 2000 leave after heart 1min, carry out single base extension in ABI9700PCR instrument.
(C) loop parameter
(5) by reaction product after resin purification, get 10nL, SpectroCHIP chip loading;
(6) pass through
mALDI-TOF Mass Spectrometry carries out mass spectrometric detection, and obtains SNP somatotype data.
Utilize Taqman method and direct Sequencing, detect same sample, gene type comes to the same thing.
3. result is judged
Rs7574865 base is that the individuality of G is liver cancer Susceptible population, and the individuality that rs7574865 base is T is the non-Susceptible population of liver cancer.
The checking of the gene type of embodiment 2SNP site rs7574865
The B-type hepatitis people that the present invention is diagnosed as liver cancer take 5480 examples is as study group, with the artificial control group of B-type hepatitis of 6139 routine non-liver cancers.All experimenters all extract genomic dna ,-20 ℃ of preservations.
Multistage case-control study result shows, the risk of the trouble liver cancer that rs7574865 base is G is high, as following table:
Visible, the present invention is directed to the methods of genotyping of SNP site rs7574865, accuracy rate is high, reliable results.
All documents of mentioning in the present invention are all quoted as a reference in this application, are just quoted separately as a reference as each piece of document.In addition should be understood that those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims limited range equally.
SEQUENCE LISTING
<110> Fudan University
Mononucleotide polymorphism site rs7574865 and application thereof that <120> is relevant to liver cancer susceptibility
<130> 201211
<160> 5
<170> PatentIn version 3.1
<210> 1
<211> 1000
<212> DNA
<213> synthetic
<220>
<221> misc_feature
<222> (501)..(501)
<223> n=G or T
<400> 1
gatcgtttgt ttcaatcctg tttatagtgg agaaccaaaa gtaaagtaat ttctcatcta 60
acagggatgg ttcaataaac tgtaacacat ttcctaccat taaaatggag ggatttctgt 120
tacgtaaaat ttggaaagca gagatatgaa taataaaatt tcatttttgt aaatgacaaa 180
atatttcatc atttacaaaa tttcataaac aacacacatg tacacattat atttttaaaa 240
atatccacaa attatatctt ttccattttt ttccattttt atttaattag gtaaacatag 300
atacacatat ggaaaggttc acacttgact gttaatacgg atgtctttga aggtagtggt 360
gtggatggag gtaaggaaaa aagaagtggg ataaaaagaa gtttgtaatt aaaaagctac 420
atgtatatta tgatctactt tatggaaaat tacatgagtg tgtatgcagt aaaagtatga 480
aaagttggtg accaaaatgt naatagtggt tatcttattt cagtggaatt tcaggggatt 540
ttttttcttt cttcttagac ttttcattat catttgactt tttacaaaga tttgcattat 600
ttaagcaatc agaaagaaat tataaagcta ttttcatcat aacaaaaatt ccattggtaa 660
aaaattttta attaatttac ataatgtgca aaaattagaa aattagaact cctaaagcaa 720
gaagtggaaa aattattcca atctgaagaa ataaaaccat tctctgatga ctgctgacat 780
ttacgaagca actctcaaag tgtccctgta cattttccat ggaacaaaaa tctgaagtct 840
atttgaacta tgtggcggaa gtattaatac cgtccaacta ctgagagaaa tggaaactga 900
agggattgct aatagctcat aaacaatagg ttagcgccta aatgacccgt aagtcaactg 960
tgggcatgag gatggcccag aaccacttcc aaaactgtga 1000
<210> 2
<211> 52
<212> DNA
<213> synthetic
<220>
<221> misc_feature
<222> (27)..(27)
<223> n=G or T
<400> 2
gtatgaaaag ttggtgacca aaatgtnaat agtggttatc ttatttcagt gg 52
<210> 3
<211> 30
<212> DNA
<213> synthetic
<400> 3
acgttggatg aatcccctga aattccactg 30
<210> 4
<211> 30
<212> DNA
<213> synthetic
<400> 4
acgttggatg gagtgtgtat gcagtaaaag 30
<210> 5
<211> 24
<212> DNA
<213> synthetic
<400> 5
tactgaaata agataaccac tatt 24
Claims (15)
1. a nucleic acid molecule relevant to liver cancer susceptibility, is characterized in that, described nucleic acid molecule comprises SNP site rs7574865, and its sequence is as shown in SEQ.ID.NO.2.
2. nucleic acid molecule as claimed in claim 1, is characterized in that, the 27th bit base of this nucleic acid molecule is G or T.
3. the STAT4 Gene Partial sequence in the hereditary region 2q32.2-32.3 relevant to liver cancer susceptibility, is characterized in that, this STAT4 Gene Partial sequence comprises sequence claimed in claim 1, and its nucleotide sequence is as shown in SEQ.ID.NO.1.
4. one group is detected the primer of SNP site rs7574865, it is characterized in that, described primer comprises specific nucleic acid primer and UEP primer, and the sequence of specific nucleic acid primer is as shown in SEQ.ID.NO.3 and SEQ.ID.NO.4, and the sequence of UEP primer is as shown in SEQ.ID.NO.5.
5. a method that detects SNP site rs7574865, is characterized in that, the step that obtains rs7574865 sequence is followed successively by:
(1) utilize the DNA of the specific nucleic acid primer amplification sample described in claim 4; The sequence of described specific nucleic acid primer is as shown in SEQ.ID.NO.3 and SEQ.ID.NO.4;
(2) product of getting step (1) is template, utilizes UEP primer to carry out single-basic extension, and the sequence of described UEP primer is as shown in SEQ.ID.NO.5;
(3) product of mass spectrometric detection step (2).
6. method as claimed in claim 5, is characterized in that, the amplification condition of step (1) is: 95 ℃ of 2min; 95 ℃ of 0.5min, 56 ℃ of 0.5min, 72 ℃ of 1min, 45 circulations; 72 ℃ of 5min, 25 ℃ of ∞ min.
7. method as claimed in claim 5, is characterized in that, the product of step (1) carries out single-basic extension after purifying again.
8. method as claimed in claim 5, is characterized in that, the condition of the described single-basic extension of step (2) is: 94 ℃ of 30s; 94 ℃ of 5s, 52 ℃ of 5s-80 ℃ of 5s, internal recycling 5 times, outer loop 40 times; 72 ℃ of 180s; 25 ℃ of ∞ s.
9. method as claimed in claim 5, is characterized in that, the concrete steps that obtain rs7574865 sequence are as follows:
In STAT4 gene, select SNP site rs7574865 and design specific nucleic acid primer and UEP primer;
According to corresponding base sequence synthetic primer SEQ.ID.NO.3, SEQ.ID.NO.4 and UEP primer SEQ.ID.NO.5; PCR reaction system 5ul:0.625ul10 × TaqBuffer, 0.125mM dNTP, 0.12ul10nM PCR primer Mix, 0.32525nM MgCl
2, 0.1ul5U/ML Hotstar enzyme, uses ddH
2o supplies 5ul; PCR reaction conditions: 95 ℃ of 2min; 95 ℃ of 0.5min, 56 ℃ of 0.5min, 72 ℃ of 1min, 45 circulations; 72 ℃ of 5min, 25 ℃ of ∞ min; SAP purification reaction system 2ul:0.17ul10 × SAPBuffer, 0.31U/ul SAP enzyme, uses ddH
2o supplies 2ul; SAP purification reaction condition: 37 ℃ of 40min, 85 ℃ of 5min, 25 ℃ of ∞ min;
Single base extension system 2ul:0.210 × iPlexBuffer, 0.2iPlex Termination, 0.33100uM stops primer Mix, and 0.041iPlex Enzyme, uses ddH
2o supplies 2ul; Single base extension condition: 94 ℃ of 30s; 94 ℃ of 5s, 52 ℃ of 5s-80 ℃ of 5s, internal recycling 5 times, outer loop 40 times; 72 ℃ of 180s; 25 ℃ of ∞ s;
Above-mentioned reaction product, after resin purification, is got to 10nL, SpectroCHIP chip loading; Pass through
mALDI-TOF Mass Spectrometry carries out mass spectrometric detection, and obtains the somatotype data of SNP site rs7574865.
10. a test kit that detects SNP site rs7574865, is characterized in that, described test kit comprises specific nucleic acid primer claimed in claim 4.
11. test kits as claimed in claim 10, is characterized in that, described test kit also comprises UEP primer, and its sequence is as shown in SEQ.ID.NO.5.
12. test kits as claimed in claim 10, is characterized in that, the damping fluid using in the PCR that described test kit also comprises.
The application of 13. nucleic acid molecule claimed in claim 1, it is characterized in that, the gene type that carries out SNP site rs7574865 by extracting experimenter's genomic dna, the individuality that rs7574865 base is G is liver cancer Susceptible population, the individuality that rs7574865 base is T is the non-Susceptible population of liver cancer.
The application of 14. test kits claimed in claim 10, is characterized in that, determines the sequence of SNP site rs7574865: the DNA of amplified sample; Then carry out single-basic extension; Last mass spectrometric detection somatotype.
15. application as claimed in claim 14, is characterized in that, utilize the genomic dna of the in vitro sample of specific nucleic acid primer amplification described in claim 4, utilize the UEP primer described in claim 4 to carry out single-basic extension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210493218.6A CN103834638A (en) | 2012-11-27 | 2012-11-27 | Single nucleotide polymorphic site rs7574865 related to liver cancer susceptibility and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210493218.6A CN103834638A (en) | 2012-11-27 | 2012-11-27 | Single nucleotide polymorphic site rs7574865 related to liver cancer susceptibility and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103834638A true CN103834638A (en) | 2014-06-04 |
Family
ID=50798535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210493218.6A Pending CN103834638A (en) | 2012-11-27 | 2012-11-27 | Single nucleotide polymorphic site rs7574865 related to liver cancer susceptibility and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103834638A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104745710A (en) * | 2015-04-16 | 2015-07-01 | 上海洛施生物科技有限公司 | SNP marker related to primary hepatocellular carcinoma auxiliary diagnosis and application of SNP marker |
| CN104830978A (en) * | 2015-04-26 | 2015-08-12 | 中国人民武装警察部队总医院 | Gene related to hepatocellular careinoma postoperative tumor recurrence and detection method thereof |
| CN106086231A (en) * | 2016-08-30 | 2016-11-09 | 长沙三济生物科技有限公司 | The Pyrosequencing primer of qualitative detection STAT4 gene type to and test kit |
| CN106480212A (en) * | 2016-11-24 | 2017-03-08 | 深圳市核子基因科技有限公司 | A kind of kit for detecting liver cancer susceptibility and its SNP mark |
| CN106834455A (en) * | 2017-01-17 | 2017-06-13 | 北京大学第医院 | The kit and method of a kind of liver cancer susceptibility of detection HBeAg feminine genders HBV chronic infection cirrhosis persons |
| CN107312828A (en) * | 2017-04-24 | 2017-11-03 | 首都医科大学附属北京佑安医院 | The mononucleotide polymorphism site related from different tumor growth rate liver cancer and its application |
| CN107557461A (en) * | 2017-10-20 | 2018-01-09 | 武汉赛云博生物科技有限公司 | A kind of mass spectrographic detection method of nucleic acid early sieved for liver cancer susceptibility |
| CN108676870A (en) * | 2018-06-29 | 2018-10-19 | 西安交通大学 | With detection method, detection kit and its application of the relevant FMO3 gene SNPs of TIA neurological susceptibilities |
| CN111635944A (en) * | 2020-07-03 | 2020-09-08 | 南方医科大学南方医院 | Specific primer, kit and PCR method for detecting liver cancer susceptibility locus rs73613962 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012109427A1 (en) * | 2011-02-10 | 2012-08-16 | Genqual Corporation | Methods of prognosing and administering treatment for inflammatory disorders |
-
2012
- 2012-11-27 CN CN201210493218.6A patent/CN103834638A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012109427A1 (en) * | 2011-02-10 | 2012-08-16 | Genqual Corporation | Methods of prognosing and administering treatment for inflammatory disorders |
Non-Patent Citations (2)
| Title |
|---|
| LI ET AL: "Association of genetic variations in the STAT4 and IRF7/KIAA1542 regions with systemic lupus erythematosus in a Northern Han Chinese population", 《HUMAN IMMUNOLOGY》, 31 December 2011 (2011-12-31), pages 249 - 255 * |
| NCBI: "Submitted SNP(ss)Details:ss276838709", 《DBSNP SHORT GENETIC VARIATIONS》, 16 December 2010 (2010-12-16) * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104745710B (en) * | 2015-04-16 | 2017-10-20 | 上海洛施生物科技有限公司 | A kind of SNP mark related to primary hepatoma auxiliary diagnosis and its application |
| CN104745710A (en) * | 2015-04-16 | 2015-07-01 | 上海洛施生物科技有限公司 | SNP marker related to primary hepatocellular carcinoma auxiliary diagnosis and application of SNP marker |
| CN104830978A (en) * | 2015-04-26 | 2015-08-12 | 中国人民武装警察部队总医院 | Gene related to hepatocellular careinoma postoperative tumor recurrence and detection method thereof |
| CN106086231A (en) * | 2016-08-30 | 2016-11-09 | 长沙三济生物科技有限公司 | The Pyrosequencing primer of qualitative detection STAT4 gene type to and test kit |
| CN106480212A (en) * | 2016-11-24 | 2017-03-08 | 深圳市核子基因科技有限公司 | A kind of kit for detecting liver cancer susceptibility and its SNP mark |
| CN106834455B (en) * | 2017-01-17 | 2021-02-09 | 北京大学第一医院 | Kit and method for detecting liver cancer susceptibility gene of HBeAg negative HBV chronic infection cirrhosis patient |
| CN106834455A (en) * | 2017-01-17 | 2017-06-13 | 北京大学第医院 | The kit and method of a kind of liver cancer susceptibility of detection HBeAg feminine genders HBV chronic infection cirrhosis persons |
| CN107312828A (en) * | 2017-04-24 | 2017-11-03 | 首都医科大学附属北京佑安医院 | The mononucleotide polymorphism site related from different tumor growth rate liver cancer and its application |
| CN107557461A (en) * | 2017-10-20 | 2018-01-09 | 武汉赛云博生物科技有限公司 | A kind of mass spectrographic detection method of nucleic acid early sieved for liver cancer susceptibility |
| CN107557461B (en) * | 2017-10-20 | 2021-02-19 | 武汉赛云博生物科技有限公司 | Detection method of nucleic acid mass spectrum for early screening of liver cancer susceptibility genes |
| CN108676870A (en) * | 2018-06-29 | 2018-10-19 | 西安交通大学 | With detection method, detection kit and its application of the relevant FMO3 gene SNPs of TIA neurological susceptibilities |
| CN108676870B (en) * | 2018-06-29 | 2021-07-13 | 西安交通大学 | Detection method and detection kit for SNP of FMO3 gene related to TIA susceptibility and application of detection kit |
| CN111635944A (en) * | 2020-07-03 | 2020-09-08 | 南方医科大学南方医院 | Specific primer, kit and PCR method for detecting liver cancer susceptibility locus rs73613962 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103834638A (en) | Single nucleotide polymorphic site rs7574865 related to liver cancer susceptibility and application thereof | |
| CN103834639A (en) | Single-nucleotide polymorphism (SNP) site rs9275319 related to liver cancer susceptibility and application thereof | |
| CN104450963B (en) | A kind of HBV DNA digital pcrs immue quantitative detection reagent box and its application | |
| WO2010043114A1 (en) | Use of serum/plasma microrna in early diagnosis of hbv infection and liver cancer | |
| CN104726570A (en) | Kit for detecting IncRNA-NEAT1 in serum and application thereof in liver cancer serological diagnosis | |
| CN110343785B (en) | Kit for detecting hepatitis B virus covalent closed circular DNA based on PCR-CRISPR-cas13a | |
| CN104388598A (en) | Digital PCR quantitative detecting kit for HBV (hepatitis B virus) cccDNA and application of digital PCR quantitative detecting kit for HBV cccDNA | |
| CN108374048B (en) | lncRNA marker for diagnosing and treating hepatocellular carcinoma | |
| CN102329860B (en) | Molecular mark related to glioblastoma multiforme treatment with temozolomide | |
| CN102912030A (en) | Primer pairs, probes and kit for early diagnosis of prostatic cancer (PC) | |
| CN101880715B (en) | Recurrence predicting reagent kit for liver cancer liver transplantation postoperation | |
| CN109536601B (en) | Modeling method of children asthma serum specific miRNAs and decision tree model | |
| CN111304326A (en) | Reagent for detecting and targeting lncRNA biomarker and application of reagent in hepatocellular carcinoma | |
| CN102912018B (en) | Kit for detecting expression index of mRNA (messager Ribose Nucleic Acid) of WT1 (Wilms Tumor 1) gene | |
| CN108384785B (en) | Circular RNA circ-GPC3, detection reagent and application thereof | |
| CN115323075B (en) | RT-RAA primer probe group and kit for detecting infectious bronchitis viruses and genotyping and application of RT-RAA primer probe group and kit | |
| CN102994495A (en) | Single nucleotide polymorphism site relevant to susceptibility of prostate cancer and application of single nucleotide polymorphism site | |
| EP2914751A1 (en) | Effect of hbv on clinical outcome of hepatocellular carcinoma cancer patients | |
| CN103751801A (en) | Application of miR-143 gene in non-small-cell lung carcinoma | |
| KR20130113046A (en) | Markers for diagnosing liver disease and its use | |
| CN108676919B (en) | HBV pgRNA fluorescent quantitative PCR detection kit | |
| CN102021169A (en) | Serum/plasma miRNA composition and use thereof | |
| US11021756B2 (en) | MiRNA markers for the diagnosis of osteosarcoma | |
| CN101195843A (en) | HBV DNA gene parting fluorescence PCR multicenter detecting method and kit thereof | |
| CN110396560A (en) | For detecting purposes and method of the product of ddcfDNA in preparation detection BKVAN product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140604 |
|
| RJ01 | Rejection of invention patent application after publication |